Sanofi opened 2026 with momentum: first-quarter sales reached €10.5 billion, up 13.6% at constant exchange rates, and business EPS rose 14% to €1.88. Growth was anchored by Dupixent, which delivered €4.2 billion and expanded 30.8%, and a cohort of newer specialty launches—Ayvakit, Altuviiio, and Sarclisa—that collectively climbed 49.6% to €1.2 billion. Vaccines ticked up 2.1% to €1.3 billion, with an early lift from Heplisav-B following the completed Dynavax acquisition. Sanofi affirmed full-year guidance for high single-digit sales growth at constant exchange rates with business EPS outpacing revenue. Alongside the P&L, the company logged five regulatory approvals in immunology, positive readouts for venglustat in type 3 Gaucher disease and lunsekimig in respiratory disease, two submission acceptances, and progressed one Phase 3 program.
Beneath the headline growth sits a strategic pivot that now looks intentional and scaled: concentrate the portfolio around immunology and specialty care while augmenting vaccines with targeted bolt-ons. The immunology approvals cluster, the respiratory pipeline signal, and the Dupixent trajectory suggest Sanofi is building a multiyear franchise architecture rather than a single-asset dependency. The Dynavax deal adds a commercial vaccine with differentiated dosing and immediate payer-facing synergies, but it also increases near-term SG&A, which rose 11.6% primarily from acquisitions. The divergence between business EPS growth and an 11.8% decline in IFRS EPS underscores ongoing transformation costs that commercial leaders must plan around as integration and launch investments pull forward.
This matters now because the immunology market is entering a new competitive phase. With multiple mechanisms vying for share across atopic, respiratory, and inflammatory conditions, maintaining Dupixent’s pace will hinge on indication expansion, real-world evidence to defend positioning, and outcomes frameworks that resonate with payers as budgets tighten. For HCPs, the pipeline breadth and five new approvals create an education burden and an opportunity: streamlined pathways for earlier intervention if data packages convincingly link symptom control to reduced exacerbations and healthcare utilization. For payers, the question shifts from single-asset affordability to portfolio value, where contracting strategies across immunology and vaccines could become decisive. Competitors will note that Sanofi’s launch engine is now producing measurable revenue, with Altuviiio and Sarclisa signaling sustained specialty depth beyond respiratory.
The vaccines story is equally strategic. Heplisav-B brings a two-dose adult hepatitis B option into a global footprint already scaled for influenza and RSV, enabling bundled tenders and integrated adult immunization campaigns. If Sanofi can translate that into higher series completion and improved population coverage, it not only accretes revenue but also strengthens its negotiation leverage in seasonal and endemic markets. The 25-year partnership milestone with WHO on sleeping sickness and a positive CHMP opinion for acoziborole further reinforce an access and global health narrative that can support stakeholder goodwill as pricing debates intensify.
Industry-wide, Sanofi’s quarter reflects two powerful currents: large-cap concentration around durable specialty franchises, and targeted M&A that is accretive on day one with clear channel synergies. The measured 1.5% increase in R&D spending alongside multiple regulatory wins suggests tighter capital allocation to late-stage, de-risked assets while keeping optionality in rare disease and respiratory mechanisms. With leadership transitioning and guidance intact, the next test is operational: can Sanofi convert its immunology stack and vaccine add-ons into contracting advantages and real-world outcomes that blunt competitive erosion? The answer will determine whether today’s double-digit growth is a launch-cycle spike or the early cadence of a more defensible, portfolio-led expansion.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
